FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2315673735> ?p ?o ?g. }

• W2315673735 endingPage "232" @default.
• W2315673735 startingPage "227" @default.
• W2315673735 abstract "Background: Evidence supported a beneficial effect of ivabradine on clinical outcome of patients with systolic heart failure, and a sinus heart rate (HR) ≥ 70 bpm. We explored the effect of ivabradine, vs. placebo, added to evidence-based treatment on exercise tolerance and quality of life in patients with idiopathic dilated cardiomyopathy. Methods: We enrolled 43 consecutive patients with dilated cardiomyopathy of no apparent cause, a left ventricular ejection fraction (LVEF) < 40%, New York Heart Association class ≥ II, sinus HR ≥ 70 bpm, and background evidence-based anti-failure medications. Ischemic heart disease was ruled out. Patients were randomized (1:1) to receive ivabradine or placebo. Ivabradine was titrated up gradually till 7.5 mg twice daily, or a HR < 60 bpm, and continued for 3 months. Symptom-limited exercise tolerance test was performed, and quality of life was assessed by the Minnesota Living With Heart Failure Questionnaire at 0, and 3 months. Results: Forty-three patients were randomized to ivabradine (n = 20), or placebo (n = 23). Mean age was 50.8 ± 14.5 years (53.5% males). Mean HR was 85 ± 12 bpm, and mean LVEF was 32 ± 6%. Mean dose of carvedilol was 31.2% of the target dose. Baseline HR, blood pressure, exercise tolerance, Minnesota questionnaire score, and left ventricular systolic function were comparable between the two groups (p > 0.05 for all). At 3 months, mean dose of ivabradine was 6.8 mg bid. Ivabradine-treated patients had a lower HR, and improved left ventricular dimensions and systolic function, versus placebo-treated ones (p < 0.05 for all). HR dropped by a mean of 14 bpm in the ivabradine group, corrected for placebo. Both exercise tolerance, and Minnesota questionnaire score were better in the ivabradine group (p < 0.05 both). Ivabradine was well-tolerated. Conclusions: In symptomatic patients with idiopathic dilated cardiomyopathy, the addition of ivabradine, vs. placebo, to evidence-based treatment, reduced HR, and improved functional capacity, at short-term follow-up." @default.
• W2315673735 created "2016-06-24" @default.
• W2315673735 creator A5023104325 @default.
• W2315673735 creator A5027962032 @default.
• W2315673735 creator A5031078257 @default.
• W2315673735 creator A5040437564 @default.
• W2315673735 creator A5042496384 @default.
• W2315673735 creator A5044755937 @default.
• W2315673735 date "2015-04-28" @default.
• W2315673735 modified "2023-10-16" @default.
• W2315673735 title "If current inhibitor ivabradine in patients with idiopathic dilated cardiomyopathy: Impact on the exercise tolerance and quality of life" @default.
• W2315673735 cites W1567648906 @default.
• W2315673735 cites W1977529073 @default.
• W2315673735 cites W1989036742 @default.
• W2315673735 cites W2001966526 @default.
• W2315673735 cites W2004777617 @default.
• W2315673735 cites W2022608906 @default.
• W2315673735 cites W2031357491 @default.
• W2315673735 cites W2046746746 @default.
• W2315673735 cites W2063484906 @default.
• W2315673735 cites W2095339761 @default.
• W2315673735 cites W2101099004 @default.
• W2315673735 cites W2129134633 @default.
• W2315673735 cites W2136642260 @default.
• W2315673735 cites W2137534212 @default.
• W2315673735 cites W2144207672 @default.
• W2315673735 cites W2147299605 @default.
• W2315673735 cites W2148910374 @default.
• W2315673735 cites W2154143064 @default.
• W2315673735 cites W2164145340 @default.
• W2315673735 cites W2427094903 @default.
• W2315673735 doi "https://doi.org/10.5603/cj.a2014.0057" @default.
• W2315673735 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25179314" @default.
• W2315673735 hasPublicationYear "2015" @default.
• W2315673735 type Work @default.
• W2315673735 sameAs 2315673735 @default.
• W2315673735 citedByCount "16" @default.
• W2315673735 countsByYear W23156737352015 @default.
• W2315673735 countsByYear W23156737352017 @default.
• W2315673735 countsByYear W23156737352018 @default.
• W2315673735 countsByYear W23156737352019 @default.
• W2315673735 countsByYear W23156737352020 @default.
• W2315673735 countsByYear W23156737352021 @default.
• W2315673735 countsByYear W23156737352023 @default.
• W2315673735 crossrefType "journal-article" @default.
• W2315673735 hasAuthorship W2315673735A5023104325 @default.
• W2315673735 hasAuthorship W2315673735A5027962032 @default.
• W2315673735 hasAuthorship W2315673735A5031078257 @default.
• W2315673735 hasAuthorship W2315673735A5040437564 @default.
• W2315673735 hasAuthorship W2315673735A5042496384 @default.
• W2315673735 hasAuthorship W2315673735A5044755937 @default.
• W2315673735 hasBestOaLocation W23156737351 @default.
• W2315673735 hasConcept C126322002 @default.
• W2315673735 hasConcept C142724271 @default.
• W2315673735 hasConcept C159110408 @default.
• W2315673735 hasConcept C164705383 @default.
• W2315673735 hasConcept C204787440 @default.
• W2315673735 hasConcept C27081682 @default.
• W2315673735 hasConcept C2776383484 @default.
• W2315673735 hasConcept C2777953023 @default.
• W2315673735 hasConcept C2778198053 @default.
• W2315673735 hasConcept C2778797674 @default.
• W2315673735 hasConcept C2779167562 @default.
• W2315673735 hasConcept C2779951463 @default.
• W2315673735 hasConcept C71924100 @default.
• W2315673735 hasConcept C78085059 @default.
• W2315673735 hasConcept C84393581 @default.
• W2315673735 hasConceptScore W2315673735C126322002 @default.
• W2315673735 hasConceptScore W2315673735C142724271 @default.
• W2315673735 hasConceptScore W2315673735C159110408 @default.
• W2315673735 hasConceptScore W2315673735C164705383 @default.
• W2315673735 hasConceptScore W2315673735C204787440 @default.
• W2315673735 hasConceptScore W2315673735C27081682 @default.
• W2315673735 hasConceptScore W2315673735C2776383484 @default.
• W2315673735 hasConceptScore W2315673735C2777953023 @default.
• W2315673735 hasConceptScore W2315673735C2778198053 @default.
• W2315673735 hasConceptScore W2315673735C2778797674 @default.
• W2315673735 hasConceptScore W2315673735C2779167562 @default.
• W2315673735 hasConceptScore W2315673735C2779951463 @default.
• W2315673735 hasConceptScore W2315673735C71924100 @default.
• W2315673735 hasConceptScore W2315673735C78085059 @default.
• W2315673735 hasConceptScore W2315673735C84393581 @default.
• W2315673735 hasIssue "2" @default.
• W2315673735 hasLocation W23156737351 @default.
• W2315673735 hasLocation W23156737352 @default.
• W2315673735 hasOpenAccess W2315673735 @default.
• W2315673735 hasPrimaryLocation W23156737351 @default.
• W2315673735 hasRelatedWork W1982732353 @default.
• W2315673735 hasRelatedWork W2025203805 @default.
• W2315673735 hasRelatedWork W2038962385 @default.
• W2315673735 hasRelatedWork W2162221761 @default.
• W2315673735 hasRelatedWork W2189032557 @default.
• W2315673735 hasRelatedWork W2381773918 @default.
• W2315673735 hasRelatedWork W2726475779 @default.
• W2315673735 hasRelatedWork W2914360403 @default.
• W2315673735 hasRelatedWork W2914770446 @default.
• W2315673735 hasRelatedWork W4245606665 @default.
• W2315673735 hasVolume "22" @default.

• next